Nephro-Urology Monthly

Published by: Kowsar

Effects of Interleukin 2 Receptor Blockers on Patient and Graft Survival in Renal-Transplanted Children

Mostafa Sharifian 1 , * , Banafsheh Arad 1 , Naser Simfroosh 1 , Abbas Basiri 1 , Hassan Otukesh 2 and Nasrin Esfandiar 1
Authors Information
1 Pediatric Infections Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 Iran University of Medical Sciences, Tehran, IR Iran
Article information
  • Nephro-Urology Monthly: July 01, 2014, 6 (4); e18641
  • Published Online: July 5, 2014
  • Article Type: Research Article
  • Received: February 28, 2014
  • Revised: March 21, 2014
  • Accepted: March 26, 2014
  • DOI: 10.5812/numonthly.18641

To Cite: Sharifian M, Arad B, Simfroosh N, Basiri A, Otukesh H, et al. Effects of Interleukin 2 Receptor Blockers on Patient and Graft Survival in Renal-Transplanted Children, Nephro-Urol Mon. 2014 ; 6(4):e18641. doi: 10.5812/numonthly.18641.

Abstract
Copyright © 2014, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Sharifian M, Rees L, Trompeter RS. High incidence of bacteriuria following renal transplantation in children. Nephrol Dial Transplant. 1998; 13(2): 432-5[PubMed]
  • 2. Atlani M, Sharma RK, Gupta A. Basiliximab induction in renal transplantation: long-term outcome. Saudi J Kidney Dis Transpl. 2013; 24(3): 473-9[PubMed]
  • 3. Talley L, Stablein MD, Berlin S, Norman A, Thotapally K, Newton A. APRTCS 2006 Annual Report, Renal Transplantation Dialysis Chronic Renal Insufficiency 2006;
  • 4. Kleigman RM, Jenson HB, Geme JWS, Schor NF, Behrman RE. Nelson Textbook of Pediatrics. 2011; : 1826
  • 5. Van Gelder T, Warle M, Ter Meulen RG. Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice? Drugs. 2004; 64(16): 1737-41[PubMed]
  • 6. Offner G, Broyer M, Niaudet P, Loirat C, Mentser M, Lemire J, et al. A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients. Transplantation. 2002; 74(7): 961-6[PubMed]
  • 7. Salis P, Caccamo C, Verzaro R, Gruttadauria S, Artero M. The role of basiliximab in the evolving renal transplantation immunosuppression protocol. Biologics. 2008; 2(2): 175-88[PubMed]
  • 8. Folkmane I, Bicans J, Amerika D, Chapenko S, Murovska M, Rosentals R. Low rate of acute rejection and cytomegalovirus infection in kidney transplant recipients with basiliximab. Transplant Proc. 2001; 33(7-8): 3209-10[PubMed]
  • 9. Ponticelli C, Yussim A, Cambi V, Legendre C, Rizzo G, Salvadori M, et al. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation. 2001; 72(7): 1261-7[PubMed]
  • 10. Sheashaa HA, Bakr MA, Ismail AM, Sobh MA, Ghoneim MA. Basiliximab reduces the incidence of acute cellular rejection in live-related-donor kidney transplantation: a three-year prospective randomized trial. J Nephrol. 2003; 16(3): 393-8[PubMed]
  • 11. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med. 1998; 338(3): 161-5[DOI][PubMed]
  • 12. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet. 1997; 350(9086): 1193-8[PubMed]
  • 13. Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation. 2004; 77(2): 166-76[DOI][PubMed]
  • 14. Chapman TM, Keating GM. Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs. 2003; 63(24): 2803-35[PubMed]
  • 15. Talley L, Stablein MD, Berlin S, Norman A, Thotapally K, Newton A. Annual report of NAPRTCS 2010, Transplantation 2010;
  • 16. ter Meulen CG, van Riemsdijk I, Hene RJ, Christiaans MH, Borm GF, van Gelder T, et al. Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter study. Am J Transplant. 2004; 4(5): 803-10[DOI][PubMed]
  • 17. Sarwal MM, Yorgin PD, Alexander S, Millan MT, Belson A, Belanger N, et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation. 2001; 72(1): 13-21[PubMed]
  • 18. Nashan B, Light S, Hardie IR, Lin A, Johnson JR. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation. 1999; 67(1): 110-5[PubMed]
  • 19. Lawen JG, Davies EA, Mourad G, Oppenheimer F, Molina MG, Rostaing L, et al. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation. 2003; 75(1): 37-43[DOI][PubMed]
  • 20. Ahsan N, Holman MJ, Jarowenko MV, Razzaque MS, Yang HC. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. Am J Transplant. 2002; 2(6): 568-73[PubMed]
  • 21. Adu D, Cockwell P, Ives NJ, Shaw J, Wheatley K. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ. 2003; 326(7393): 789[DOI][PubMed]
  • 22. Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation. 2003; 76(9): 1289-93[DOI][PubMed]
  • 23. Patlolla V, Zhong X, Reed GW, Mandelbrot DA. Efficacy of anti-IL-2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation. Am J Transplant. 2007; 7(7): 1832-42[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments